Sugi Predict

Sugi Predict / Compounds / SCHEMBL615392

SCHEMBL615392

SCHEMBL615392

CCCCOc1ccc(S(N)(=O)=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 14/20 1.00
▸ CA1 P00915 12/20 1.00
▸ CA9 Q16790 12/20 1.00
▸ CA12 O43570 11/20 1.00
▸ CA7 P43166 8/20 1.00
▸ TSHR P16473 1/20 1.00
▸ CA4 P22748 6/20 0.63
▸ HRH3 Q9Y5N1 5/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ KCNH2 Q12809 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1376263 0.96 CA2 (0.93) CA2CA1CA9CA12CA7
SCHEMBL1333401 0.95 CA2 (0.90) CA2CA1CA9CA12CA7
SCHEMBL8618402 0.95 CA2 (0.90) CA2CA1CA9CA12CA7
SCHEMBL10822914 0.95 CA2 (0.90) CA2CA1CA9CA12CA7
SCHEMBL6550862 0.95 CA2 (0.90) CA2CA1CA9CA12CA7
SCHEMBL9848224 0.95 CA2 (0.90) CA2CA1CA9CA12CA7
SCHEMBL5595956 0.92 CA1 (1.00) CA2CA1CA9CA12CA7
SCHEMBL4641038 0.89 CA1 (0.79) CA2CA1CA9CA12CA7
SCHEMBL19891669 0.88 CA12 (0.79) CA2CA1CA9CA12CA7
SCHEMBL18361755 0.87 CA1 (0.77) CA2CA1CA9CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 — — US claimed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 — — US claimed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 — — EP claimed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 — — US claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 — — EP claimed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 — — US claimed
CN-1177832-C Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion ���ĵ�˹ҩƷ�¹��ɷ����޹�˾ 2004-12-01 — — CN claimed
US-20020065271-A1 Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion PEYMAN ANUSCHIRWAN (DE) 2002-05-30 — — US claimed
US-6313119-B1 VITRONECTIN RECEPTOR ANTAGONISTS ADVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-11-06 — — US claimed
CN-1293662-A Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion AIWENTIS DRUG DEUTSCHLAND GMBH (DE) 2001-05-02 — — CN claimed
EP-1049677-A1 NOVEL SULFONAMIDE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS INHIBITORS OF CELL ADHESION Aventis Pharma Deutschland GmbH (DE) 2000-11-08 — — EP claimed
WO-1999037621-A1 NOVEL SULFONAMIDE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS INHIBITORS OF CELL ADHESION AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 1999-07-29 — — WO claimed
US-12583818-B2 Compound, preparation method thereof, and use thereof DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2026-03-24 — — US disclosed
CN-119219808-A Multifunctional ionic polymer, preparation method and application thereof, and ion exchange membrane 佛山绿动氢能科技有限公司 2024-12-31 — — CN disclosed
CN-114981241-A Novel compound, preparation method and application thereof 大邱庆北尖端医疗产业振兴财团 2022-08-30 — — CN disclosed
US-20220180083-A1 MODIFYING MESSAGES STORED IN MIXTURES OF MOLECULES USING THIN-LAYER CHROMATOGRAPHY NORTHWESTERN UNIVERSITY 2022-06-09 — — US disclosed
EP-0562512-A1 Sulfonamido- and sulfonamidocarbonyl-pyridine-2-carboxamides and their pyridine-N-oxides, process for their preparation and their use as medicines HOECHST AKTIENGESELLSCHAFT (DE) 1993-09-29 — — EP disclosed
US-5229248-A Hydrazine compound or derivative and amines or quaternary ammonium compounds, high contrast KONICA CORPORATION (JP) 1993-07-20 — — US disclosed
EP-0510526-A1 Use of sulfonamides as drug and new sulfonamides F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) 1992-10-28 — — EP disclosed
EP-0473342-A1 Silver halide photographic light sensitive material KONICA CORPORATION (JP) 1992-03-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583818-B2 Compound, preparation method thereof, and use thereof TYRO3, TH, SRMS CA2 2241/4885CA1 1920/4885CA9 1421/4885
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 CA2 2765/4885CA1 902/4885CA9 2476/4885
US-20050107307-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 CA2 2765/4885CA1 902/4885CA9 2476/4885
US-20020065271-A1 Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion SOST, SELPLG, BST2 CA2 667/4885CA1 957/4885CA9 1482/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 CA2 2765/4885CA1 902/4885CA9 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.